{"id":392678,"date":"2020-12-03T08:33:32","date_gmt":"2020-12-03T13:33:32","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392678"},"modified":"2020-12-03T08:33:32","modified_gmt":"2020-12-03T13:33:32","slug":"independent-discovery-validates-noxopharms-darrt-cancer-therapy-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/","title":{"rendered":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy<\/b><\/p>\n<p>SYDNEY&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAustralian clinical-stage drug development company, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.noxopharm.com%2F&amp;esheet=52341871&amp;newsitemid=20201203005226&amp;lan=en-US&amp;anchor=Noxopharm&amp;index=1&amp;md5=f92a1beca5a916ce26ecb26efcfccb3a\">Noxopharm<\/a> (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda\u00ae, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer.\n<\/p>\n<p>\nAn abscopal response \u2060\u2014 an extraordinarily rare and elusive phenomenon \u2060\u2014 can follow the delivery of a low dose of radiation to a single tumor, triggering an immune response that results in other tumors throughout the body \u201cmelting\u201d away in a matter of weeks. Patients who experience a complete abscopal response generally remain in remission for life. The radiation-induced abscopal response is highly prized as being the most cost-effective, least intrusive, and best-tolerated form of immuno-oncology therapy.\n<\/p>\n<p>\nThe Weill Cornell team identified radiation-induced damage to the cancer cells, and blocking their repair by a process known as autophagy, as fundamental to generating the abscopal response.\n<\/p>\n<p>\nThe active ingredient in Veyonda, idronoxil, is known to block autophagy.\n<\/p>\n<p>\n\u201cFor the overwhelming majority of patients, once a cancer spreads from its point of origin and becomes metastatic, the best that current treatments offer is to delay the inevitable,\u201d said <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.noxopharm.com%2Fsite%2Fabout-us%2Fboard-of-directors&amp;esheet=52341871&amp;newsitemid=20201203005226&amp;lan=en-US&amp;anchor=Graham+Kelly&amp;index=2&amp;md5=cd3675e0786e5e3aa0dff7738d0e1473\">Graham Kelly<\/a>, Noxopharm CEO and managing director. \u201cBut the clinical data shows that Veyonda very clearly is boosting the chances of triggering an abscopal response. The Weill Cornell discovery, combined with what we learned from the DARRT-1 study about Veyonda dosing, means we go into the upcoming DARRT-2 study with a high degree of confidence that we are on the edge of a major breakthrough in cancer therapy.\u201d\n<\/p>\n<p>\nNoxopharm will now test the ability of Veyonda to induce abscopal effects in a Phase II study involving about 200 patients. DARRT-2 is a Phase II multinational study, currently being planned for a start in early 2021.\n<\/p>\n<p><b>About Noxopharm <\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.noxopharm.com%2F&amp;esheet=52341871&amp;newsitemid=20201203005226&amp;lan=en-US&amp;anchor=Noxopharm&amp;index=3&amp;md5=f61e33717a968500f4174e2fd67e52dc\">Noxopharm<\/a> is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The company has a primary focus on the development of Veyonda\u00ae and is the major shareholder in the non-oncology drug development company, Nyrada Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201203005226\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201203005226\/en\/<\/a><\/span><\/p>\n<p>\nJane Byram<br \/>\n<br \/>SCORR Marketing<br \/>\n<br \/>512-626-2758<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jane@scorrmarketing.com\">jane@scorrmarketing.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York Australia\/Oceania Australia United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Radiology Biotechnology Pharmaceutical Oncology General Health Health Hospitals Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201203005226\/en\/773607\/3\/NOXOPHARM-RGB_Reduced_347x202.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy SYDNEY&#8211;(BUSINESS WIRE)&#8211; Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda\u00ae, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer. An abscopal response \u2060\u2014 an extraordinarily rare and elusive phenomenon \u2060\u2014 can follow the delivery of a low dose of radiation to a single tumor, triggering an immune response that results in other tumors throughout the body \u201cmelting\u201d away in a matter of weeks. Patients who experience a complete abscopal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392678","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy SYDNEY&#8211;(BUSINESS WIRE)&#8211; Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda\u00ae, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer. An abscopal response \u2060\u2014 an extraordinarily rare and elusive phenomenon \u2060\u2014 can follow the delivery of a low dose of radiation to a single tumor, triggering an immune response that results in other tumors throughout the body \u201cmelting\u201d away in a matter of weeks. Patients who experience a complete abscopal &hellip; Continue reading &quot;Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T13:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy\",\"datePublished\":\"2020-12-03T13:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/\"},\"wordCount\":416,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/\",\"name\":\"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-03T13:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/","og_locale":"en_US","og_type":"article","og_title":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk","og_description":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy SYDNEY&#8211;(BUSINESS WIRE)&#8211; Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda\u00ae, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer. An abscopal response \u2060\u2014 an extraordinarily rare and elusive phenomenon \u2060\u2014 can follow the delivery of a low dose of radiation to a single tumor, triggering an immune response that results in other tumors throughout the body \u201cmelting\u201d away in a matter of weeks. Patients who experience a complete abscopal &hellip; Continue reading \"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T13:33:32+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy","datePublished":"2020-12-03T13:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/"},"wordCount":416,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/","name":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-03T13:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201203005226r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/independent-discovery-validates-noxopharms-darrt-cancer-therapy-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Independent Discovery Validates Noxopharm\u2019s DARRT Cancer Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392678"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392678\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}